tetano
Editor, Senior Moderator
Dermatol Ther
. 2020 Aug 10.
doi: 10.1111/dth.14170. Online ahead of print.
Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study
Alba Catal?[SUP] 1 [/SUP], Cristina Galv?n-Casas[SUP] 2 [/SUP], Gregorio Carretero-Hern?ndez[SUP] 3 [/SUP], Pedro Rodr?guez-Jim?nez[SUP] 4 [/SUP], Daniel Fern?ndez-Nieto[SUP] 5 [/SUP], Ana Rodr?guez-Villa[SUP] 6 [/SUP], ??igo Navarro-Fern?ndez[SUP] 7 [/SUP], Ricardo Ruiz-Villaverde[SUP] 8 [/SUP], Daniel Falkenhain-L?pez[SUP] 9 [/SUP], Mar Llamas-Velasco[SUP] 4 [/SUP], Luc?a Carnero-Gonzalez[SUP] 10 [/SUP], Juan Garc?a-Gavin[SUP] 11 [/SUP], Ofelia Baniandr?s[SUP] 12 [/SUP], Carlos Gonz?lez-Cruz[SUP] 13 [/SUP], V?ctor Morillas-Lahuerta[SUP] 14 [/SUP], Xavier Cubir?[SUP] 15 [/SUP], Ignasi Figueras[SUP] 16 [/SUP], Gerald Selda-Enriquez[SUP] 5 [/SUP], Xavier Fust?-Novell[SUP] 17 [/SUP], M?nica Roncero-Riesco[SUP] 18 [/SUP], Patr?cia Burgos-Blasco[SUP] 5 [/SUP], Jorge Roman?[SUP] 19 [/SUP], Joaquim Sol?-Ortigosa[SUP] 20 [/SUP], Ignacio Garc?a-Doval[SUP] 21 [/SUP]
Affiliations
Abstract
Background: A previous study has defined the maculopapular subtype of manifestations of COVID-19.
Objectives: To describe and classify maculopapular eruptions associated with COVI-19.
Methods: We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined 7 clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern.
Results: Consensus lead to the description of 7 major maculopapular patterns: Morbilliform (45.5%), Other maculopapular (20.0%), Purpuric (14.2%), Erythema multiforme-like (9.7%), Pytiriasis rosea-like (5.7%), Erythema elevatum diutinum-like (2.3%) and Perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6.
Limitations: The impossibility to define the cause-effect relationship of each pattern.
Conclusion: We provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Coronavirus; Cutaneous Manifestations; Skin.
. 2020 Aug 10.
doi: 10.1111/dth.14170. Online ahead of print.
Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study
Alba Catal?[SUP] 1 [/SUP], Cristina Galv?n-Casas[SUP] 2 [/SUP], Gregorio Carretero-Hern?ndez[SUP] 3 [/SUP], Pedro Rodr?guez-Jim?nez[SUP] 4 [/SUP], Daniel Fern?ndez-Nieto[SUP] 5 [/SUP], Ana Rodr?guez-Villa[SUP] 6 [/SUP], ??igo Navarro-Fern?ndez[SUP] 7 [/SUP], Ricardo Ruiz-Villaverde[SUP] 8 [/SUP], Daniel Falkenhain-L?pez[SUP] 9 [/SUP], Mar Llamas-Velasco[SUP] 4 [/SUP], Luc?a Carnero-Gonzalez[SUP] 10 [/SUP], Juan Garc?a-Gavin[SUP] 11 [/SUP], Ofelia Baniandr?s[SUP] 12 [/SUP], Carlos Gonz?lez-Cruz[SUP] 13 [/SUP], V?ctor Morillas-Lahuerta[SUP] 14 [/SUP], Xavier Cubir?[SUP] 15 [/SUP], Ignasi Figueras[SUP] 16 [/SUP], Gerald Selda-Enriquez[SUP] 5 [/SUP], Xavier Fust?-Novell[SUP] 17 [/SUP], M?nica Roncero-Riesco[SUP] 18 [/SUP], Patr?cia Burgos-Blasco[SUP] 5 [/SUP], Jorge Roman?[SUP] 19 [/SUP], Joaquim Sol?-Ortigosa[SUP] 20 [/SUP], Ignacio Garc?a-Doval[SUP] 21 [/SUP]
Affiliations
- PMID: 32779280
- DOI: 10.1111/dth.14170
Abstract
Background: A previous study has defined the maculopapular subtype of manifestations of COVID-19.
Objectives: To describe and classify maculopapular eruptions associated with COVI-19.
Methods: We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined 7 clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern.
Results: Consensus lead to the description of 7 major maculopapular patterns: Morbilliform (45.5%), Other maculopapular (20.0%), Purpuric (14.2%), Erythema multiforme-like (9.7%), Pytiriasis rosea-like (5.7%), Erythema elevatum diutinum-like (2.3%) and Perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6.
Limitations: The impossibility to define the cause-effect relationship of each pattern.
Conclusion: We provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Coronavirus; Cutaneous Manifestations; Skin.